Copernicus Capital Management’s Pfizer PFE Stock Holding History

Copernicus Capital Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$1.29M	Buy	+30,000	New	+$1.33M	15.61%	1

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Copernicus Capital Management's PFE Position: Q3 2021 in Review

Copernicus Capital Management opened a new position in Pfizer (PFE) in Q3 2021: 30,000 shares worth $1.29M. The stake represents 15.61% of the portfolio and ranks #1 among its holdings.

2,803 funds tracked by Wall St. Rank hold PFE as of Q3 2021.

Copernicus Capital Management held 30,000 shares of Pfizer worth $1.29M as of Q3 2021.
Pfizer was a new Copernicus Capital Management position in Q3 2021.
Pfizer made up 15.61% of Copernicus Capital Management's portfolio in Q3 2021, its #1 holding.
2,803 funds tracked by Wall St. Rank held Pfizer as of Q3 2021.

Based on Copernicus Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.